Phosphorylation of Protein Inhibitor of Activated STAT1 (PIAS1) by MAPK-Activated Protein Kinase-2 Inhibits Endothelial Inflammation via Increasing Both PIAS1 Transrepression and SUMO E3 Ligase Activity
Objective—Protein inhibitor of activated signal transducer and activator of transcription-1 (PIAS1) is known to function as small ubiquitin-like modifier (SUMO) E3 ligase as well as transrepressor. The aim of the study is to elucidate the regulatory mechanisms for these 2 different functions, especially with respect to endothelial inflammation.
Methods and Results—The mitogen-activated protein kinase (MAPK)-activated protein kinase-2 is a proinflammatory kinase and phosphorylates PIAS1 at the Ser522 residue. Activation of MAPK-activated protein kinase-2 enhances p53-SUMOylation, but a PIAS1 phosphorylation mutant, PIAS1-S522A, abolished this p53-SUMOylation, suggesting a critical role for PIAS1-S522 phosphorylation in its SUMO ligase activity. Because nuclear p53 can inhibit Kruppel-like factor 2 promoter activity, we investigated the roles for PIAS1 phosphorylation and p53-SUMOylation in the Kruppel-like factor 2 and endothelial NO synthase expression. Both MAPK-activated protein kinase-2 and PIAS1 overexpression increased Kruppel-like factor 2 promoter activity and endothelial NO synthase expression, which were inhibited by expressing a p53-SUMOylation defective mutant, p53-K386R, and PIAS1-S522A. PIAS1-S522A also abolished the anti-inflammatory effect of wild-type PIAS1 in vitro and also in vivo, which was examined by leukocyte rolling in microvessels of skin grafts transduced by adenovirus encoding PIAS1-WT or - S522A mutant.
Conclusion—Our study has identified a novel negative feedback regulatory pathway through which MAPK-activated protein kinase-2 limits endothelial inflammation via the PIAS1 S522 phosphorylation-mediated increase in PIAS1 transrepression and SUMO ligase activity.
- endothelial inflammation
- MAPK-activated protein kinase-2
- nuclear factor-κB transrepression
- protein inhibitor of activated signal transducer and activator of transcription-1
- vascular biology
Endothelial dysfunction and subsequent atherosclerosis are characterized by chronic endothelial cell (EC) inflammation that is induced by a combination of risk factors such as hypertension, obesity, diabetes mellitus, smoking, hyperlipidemia, and genetics,1 and by the accumulation of lipids, leukocytes, and fibrous elements to form arterial plaques.2,3 Nuclear factor-κB (NF-κB) is an important transcriptional regulator of many inflammatory genes, such as those of chemokines, adhesion molecules, and cytokines that play major roles in endothelial inflammation and dysfunction. Protein modifications like phosphorylation, small ubiquitin-like modifier (SUMO)ylation, and ubiquitination have come into focus as important regulators of signaling attributable to the transient nature of these modifications that affect EC phenotypes, a characteristic found in microvascular diseases where persistent activation of NF-κB contributes to inflammation and progressive compromise of the endothelial function.4,5 Although many studies have identified key positive regulators of NF-κB signaling, much less is understood about negative feedback mechanisms that downregulate NF-κB–mediated endothelial inflammation in vascular pathologies.
Tumor necrosis factor-α (TNF-α) is a key proinflammatory cytokine involved in the progression of endothelial inflammation and dysfunction through the activation of NF-κB signaling.6 Through the canonical NF-κB pathway, TNF activates IκB kinase (IKK) to phosphorylate and degrade IκB, releasing NF-κB into the nucleus where it can activate the transcription of inflammatory genes. Protein inhibitor of activated signal transducer and activator of transcription-1 (PIAS1) negatively regulates this pathway by interacting with NF-κB to repress its transcriptional activity, affecting 48% of the TNF-induced genes.7 Not surprisingly, PIAS1-deficient mice are hypersensitive to lipopolysaccharides-induced endotoxic shock.7 Recently, Liu et al8 have reported that phosphorylation of PIAS1 at Ser-90 (S90) by IKKα during TNF-induced inflammation blocks its NF-κB repressive function, which acts as a negative feedback mechanism against the TNF–IKKα–NF-κB signaling pathway. However, the regulation of PIAS1’s transrepression of NF-κB in EC remains poorly understood.
In this study, we report that MAPK-activated protein kinase-2 (MK2) phosphorylates PIAS1 at Ser522 (S522) and promotes PIAS1 transrepression activity on NF-κB. In addition to the previously reported anti-inflammatory effect of IKKα-mediated PIAS1 S90 phosphorylation,8 we found that phosphorylation of PIAS1 S522 increased its SUMO E3 ligase activity and subsequent p53-SUMOylation. It was reported that nuclear p53 promoted endothelial inflammation by downregulating Kruppel-like factor 2 (KLF2),9 and we found that the MK2-mediated phosphorylation of PIAS1 S522 and subsequent p53-SUMOylation, which causes its nuclear export in EC,10 increased KLF2 promoter activity as well as endothelial NO synthase (eNOS) expression. The anti-inflammatory effect of PIAS1-wild type (WT) was lost in ECs expressing the PIAS1-S522A mutant protein, suggesting that the MK2-mediated PIAS1 phosphorylation at S522 protects ECs against inflammation.
Materials and Methods
An expanded version of the Methods section is available in the online-only Data Supplement.
Generation of Human Anti–Phospho-PIAS1-S522 Antibody
A peptide corresponding to amino acids 512 to 532 of human PIAS1 (PAVDTSYINTS*LIQDYRHPFH) was synthesized (Peptibody Inc, Charlotte, NC) with an amino terminus biotin label in both phosphorylated and unphosphorylated forms.
Human umbilical vein ECs (HUVECs) were obtained by collagenase digestion11 and cultured on 0.2% gelatin precoated dishes using M200 medium supplemented with low serum growth supplement (LSGS, GIBCO) and 2% fetal calf serum (GIBCO). Mouse brain ECs (bEND.3) were cultured in Dulbecco’s modified Eagle’s medium with 4 mmol/L L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate and 4.5 g/L glucose with 10% fetal bovine serum.
EC Transfection and Luciferase Reporter Assay
Fully confluent HUVECs were transfected with pNF-κB-luc reporter plasmid which contained 5 copies of the consensus NF-κB sequence linked to a minimal E1B promoter-luciferase gene (Stratagene) or KLF2-luc reporter plasmid with pRL-TK (encoding Renilla luciferase) plasmid, which was used to normalize transfection efficiencies.
Adenovirus-Mediated Gene Transfer
Fully confluent HUVECs were transduced with adenovirus vectors for LacZ (Ad-LacZ), WT MK2 (Ad-WT-MK2), and dominant-negative MK2 (Ad-DN-MK2) in fresh medium for 18 hours before being treated with TNF.
Identification of MK2-Mediated PIAS1 Phosphorylation Sites
PIAS1 phosphorylation sites were identified by a combination of NetPhos 2.012 analysis and in vitro kinase assays.
Real-Time Polymerase Chain Reaction Assay
Total RNA was extracted using the TRIzol reagent according to the manufacturer’s instruction. Reverse transcriptions were performed in 20 μL mixture containing 1 μg of total RNA according to the manufacture’s protocol (Bio-Rad, #170–8890).
Immunoprecipitation (SUMO Assay) and Western Blot Analysis
SUMOylation was detected by immunoprecipitation analysis as previously described.10
Seven- to 8-week-old C57BL/6 (Jackson Labs) mice were anesthetized with ketamine and xylazine (80/13 mg/kg). Autologous skin transplants were performed by removing a skin piece from an ear and transplanting it to the flank of the same mouse.
Intravital microscope analyses of the skin graft were carried out 1 week after transplants were made as previously described13 with some modification.
Data are reported as mean±SD as indicated. Statistical analysis was performed with the PRISM version 5.0 (GraphPad software). Differences were analyzed with a 1-way or a 2-way repeated-measure ANOVA as appropriate, followed by Schéffe’s correction for multiple comparisons.
MK2 Phosphorylates PIAS1 S522 and Inhibits TNF-Mediated NF-κB Transactivation in ECs
PIAS1 is a known negative regulator of NF-κB signaling as it interacts with p65 and represses the transcriptional activity of NF-κB.7 However, the role of PIAS1 in endothelial inflammation remains unclear. We explored this question by expressing varying amounts of either PIAS1-WT or PIAS1 small interfering RNA (siRNA) in HUVECs and then assaying for NF-κB reporter activity after TNF stimulation. Under these inflammatory conditions, expression of WT PIAS1 repressed NF-κB transactivation (Figure 1A), whereas knockdown of endogenous PIAS1 with siRNA enhanced NF-κB transcriptional activity (Figure 1B) in a dose-dependent manner.
Both IKKα and MK2 are known inflammatory kinases.15 We found that the canonical NF-κB pathway involving IKKα, IκBα, and p65 NF-κB phosphorylation was unaffected by the expression of the adenoviral WT MK2 (Ad-WT-MK2) or dominant-negative MK2 (Ad-DN-MK2) as seen in Figure I in the online-only Data Supplement. Therefore, we hypothesized that MK2 could phosphorylate PIAS1 and inhibit its transcriptional repression on NF-κB, similar to TNF activating IKKα to phosphorylate PIAS1.8 As the first step to identify phosphorylation sites in PIAS1,12 we constructed glutathione S-transferase fused truncated PIAS1 fragments (AA1-257, 231–456, 431–651, 431–550, 551–651) and used them as substrates for in vitro kinase assays with recombinant active MK2. As shown in Figure 1C and 1D, MK2 strongly phosphorylated the PIAS1 fragment containing amino acid residues 431 to 550. Using NetPhos 2.0, we then identified serine-510, -517, and -522 residues as candidates for MK2-mediated phosphorylation sites based on their high scores as potential phosphorylation sites.12 As shown in Figure II in the online-only Data Supplement, there is a significant reduction in PIAS1 AA431-651 phosphorylation in all 3 phosphorylation mutants.
After the identification of MK2-mediated PIAS1 phosphorylation sites, we used the PIAS1 phosphorylation mutants to assay for NF-κB transactivation. The PIAS1-S510A mutant behaved similarly to PIAS1-WT and the PIAS1-S517A partially repressed NF-κB transcriptional activity at 2 µg/mL of cDNA (Figure 1E). However, the PIAS1-S522A mutant lost its ability to repress NF-κB, suggesting that phosphorylation of PIAS1 S522 can functionally inhibit NF-κB transactivation.
PIAS1 S522 Is Phosphorylated by TNF Treatment via Endogenous MK2 Activation and Subsequently Inhibits NF-kB Activation
To determine the role of endogenous MK2-mediated PIAS1 S522 phosphorylation in NF-κB activation in ECs, we investigated whether TNF could increase endogenous PIAS1 S522 phosphorylation using a synthetic human antibody against phospho-PIAS1-S522 we generated by employing a phase display system. As shown in Figure 1F, TNF increased endogenous PIAS1 S522 phosphorylation maximally within 10 minutes after TNF stimulation. Finally, to determine the role of endogenous MK2 in PIAS1 S522 phosphorylation inside cells, we used MK2 siRNA and found that endogenous PIAS1 S522 phosphorylation was completely inhibited by the depletion of MK2, supporting a crucial role of endogenous MK2 in TNF-initiated PIAS1 S522 phosphorylation.
Next, to determine the role of endogenous PIAS1 S522 phosphorylation in TNF-initiated NF-κB activation, we performed knock-in experiments as shown in Figure 1G. HUVECs were treated with PIAS1 siRNA for 48 hours to deplete endogenous PIAS1 and transduced with adenovirus containing PIAS1-WT or PIAS1-S522A mutant. Expression levels of PIAS1-WT and the PIAS1-S522A mutant were similar to that of endogenous PIAS1, and we also confirmed that PIAS1-S522 phosphorylation did not occur in the PIAS1-S522A mutant knocked-in cells (Figure 1G, upper panel). As shown in Figure 1H, PIAS1-S522A mutation significantly enhanced TNF-induced NF-κB activation compared with WT. These results suggest an inhibitory role of endogenous PIAS1 S522 phosphorylation in NF-κB activation.
Critical Roles of MK2 and PIAS1 S522 Phosphorylation in Endogenous p53-SUMOylation
It has been reported that IKKα-mediated PIAS1 S90 phosphorylation inhibits NF-κB transactivation but that the PIAS1-S90A mutant retains its SUMO E3 ligase activity.8 In Figure 1 we demonstrate a role of MK2 on PIAS1 S522 phosphorylation, which inhibits NF-κB activation, but the role of MK2-mediated PIAS1 S522 phosphorylation in its SUMO E3 ligase activity remains unclear. Because we recently reported that disturbed flow-induced EC dysfunction may be mediated by p53-SUMOylation,10 first we investigated whether MK2 kinase activity could regulate p53-SUMOylation. As shown in Figure 2A, p53-SUMOylation induced by Ubc9 (SUMO E2 conjugating enzyme) and SUMO3 was significantly enhanced in cells cotransfected with MK2 but was completely abolished by kinase defective mutant DN-MK2. Next, to determine the role of endogenous MK2 in TNF-induced p53-SUMOylation, we depleted MK2 expression by using siRNA, and found that the depletion of MK2 significantly inhibited TNF-induced endogenous p53-SUMOylation in both HUVECs and bEND.3 (Figure 2B and Figure IIIA in the online-only Data Supplement), suggesting a key role of MK2 on TNF-induced p53-SUMOylation in ECs.
Next we examined the role of PIAS1 S522 phosphorylation in endogenous p53-SUMOylation in both HUVECs and bEND.3. We transduced adenovirus containing PIAS1-WT (Ad-PIAS1-WT) and -S522A mutant (Ad-PIAS1-S522A) and examined endogenous p53-SUMOylation induced by TNF (Figure 2C and Figure IIIC in the online-only Data Supplement). In addition, to examine the role of MK2-mediated PIAS1-S522 phosphorylation in endogenous p53-SUMOylation, we also transduce Ad-MK2 and examined the effect of PIAS1-S522A mutant on MK2-mediated p53-SUMOylation. As shown in Figure 2C and 2D and Figure IIIC in the online-only Data Supplement, both TNF and MK2 transduction increased endogenous p53-SUMOylation in PIAS1-WT transduced ECs. However, in PIAS1-S522A mutant transduced cells we did not find any increase of endogenous p53-SUMOylation induced by TNF, MK2, and the combination of MK2 transduction with TNF stimulation. Of note, PIAS1-WT and -S522A expression levels were similar. We also observed similar tendency that deletion of MK2 and PIAS1-S522A expression inhibited TNF-induced p53-SUMOylation in bEND.3 cells (Figure 2B–2D and Figure IIIA and IIIC in the online-only Data Supplement), demonstrating the importance of MK2 and PIAS1 S522 phosphorylation in p53-SUMOylation not only in HUVECs but also in bEND.3 cells.
Because PIAS1-S517 partially repressed NF-κB transcriptional activity, we also examined the effect of PIAS1 S517 phosphorylation on the p53-SUMOylation and found that PIAS1 S517 overexpression failed to inhibit TNF-mediated p53-SUMOylation (Figure IIIB in the online-only Data Supplement). It suggests that TNF-induced PIAS1 S522 phosphorylation but not S517 phosphorylation and can regulate p53 SUMOylation.
Roles of MK2-Mediated PIAS1 S522 Phosphorylation and Subsequent p53-SUMOylation in KLF2 Activity and eNOS Expression
Recently, Kumar et al16 reported that KLF2 expression was suppressed by p53 via the conserved p53-binding repressor sequence in its promoter (−221 to −88). We have reported that p53-SUMOylation induces p53 nuclear export.10 Therefore, we hypothesized that p53-SUMOylation induced by MK2-mediated PIAS1 S522 phosphorylation would increase KLF2 promoter activity as well as eNOS expression, which is regulated by KLF2. First, we investigated the role of MK2 and PIAS1 in KLF2 promoter activity using KLF2-luc promoter (−924 to +14) plasmid and pRL-TK plasmid used to normalize transfection efficiencies. As shown in Figure 3A, overexpression of MK2 and PIAS1-WT significantly increased KLF2 promoter activity. Although cotransduction of p53-WT did not significantly change the MK2 and PIAS1-mediated increase of KLF2 promoter activity compared with Ad-LacZ (data not shown), the Ad-p53-KR mutant significantly inhibited KLF2 promoter activity, suggesting a critical role of p53-SUMOylation in the MK2- and PIAS1-mediated KLF2 promoter activity (Figure 3A). Effects of p53-KR on KLF2 target genes were also examined. As shown in Figure 3B, transduction of Ad-MK2 and Ad-PIAS1 increased eNOS expression. Interestingly, the p53-SUMOylation KR mutant significantly inhibited eNOS expression compared with p53-WT. Next, we studied the role of MK2-mediated PIAS1 S522 phosphorylation in KLF2 promoter activity. As shown in Figure 3C, transduction of Ad-PIAS1-S522A mutant but not WT significantly inhibited MK2-mediated KLF2 promoter activity. We also found that transduction of Ad-PIAS1-S522A inhibited eNOS expression induced by MK2 overexpression (Figure 3D). Taken together, these data support a critical role of PIAS1 S522 phosphorylation and subsequent p53-SUMOylation in MK2-mediated KLF2 and eNOS expression.
MK2-Mediated PIAS1 Phosphorylation Inhibits Inflammatory Genes Expression Under TNF Stimulation
We found that PIAS1 S522 phosphorylation by MK2 suppressed NF-κB transactivation (Figure 1E and 1H). To test whether MK2-mediated PIAS1 phosphorylation and its transrepression of NF-κB were involved in EC inflammation, we transduced ECs with Ad-PIAS1-WT and Ad-PIAS1-S522A to assay for the expression of proinflammatory genes regulated by NF-κB (Figure 4A–4D). We found that overexpression of Ad-PIAS1-WT significantly inhibited the TNF-induced E-selectin, intercellular adhesion molecule–1, vascular cell adhesion molecule (VCAM-1), and membrane cofactor protein-1 mRNA expression in ECs, but interestingly this inhibitory effect was lost for the Ad-PIAS1-S522A mutant (Figure 4A–4D). We confirmed that the protein expression levels of Ad-PIAS1-WT and Ad-PIAS1-S522A were similar in ECs (Figure 4E). These data suggest a crucial role of PIAS1 S522 phosphorylation in TNF-mediated negative feedback mechanism against endothelial inflammation (Figure 4F).
PIAS1 Ser522 Phosphorylation Inhibits TNF-Mediated Endothelial Inflammation and Leukocyte Rolling In Vivo
Velocity of leukocyte rolling is a good indicator for evaluating the inflammatory state of the endothelium. To study the role of PIAS1 S522 phosphorylation in vivo, we examined leukocyte rolling in microvessels using a mouse skin graft model. To avoid transplant rejection, we used an autologous skin transplant in which a piece of skin from an ear of a C57BL/6 mouse was grafted onto the flank of the same animal. It has previously been demonstrated that grafted skin is vascularized and that leukocytes can be imaged in microvessels within the graft.13 First we transduced ear skin preparations with Ad-LacZ, Ad-PIAS1, or Ad-PIAS1-S522A for 1 hour and then transplanted them to the graft bed. Seven days after transplantation, we examined the transduction efficiency of the adenovirus vector by β-gal staining (Figure VIA in the online-only Data Supplement). We detected β-gal staining in Ad-LacZ transduced skin grafts but not in nontransduced grafts. In addition, PIAS1 expression was ≈2-fold increased by transduction of Ad-PIAS1 and -PIAS1-S522A compared with Ad-LacZ (Figure VIB in the online-only Data Supplement). Using intravital microscopy, we next studied leukocyte rolling in microvessels 3 hours after peritoneal injection of saline or TNF.17 Leukocyte rolling velocity was determined by measuring the distance that each leukocyte traveled along the vessel wall between 2 successive frames (Figure 5A). The baseline leukocyte rolling velocity showed no significant differences among Ad-LacZ, Ad-PIAS1-WT, and Ad-PIAS1-S522A-transduced skin grafts (Figure 5B and Movies I–III in the online-only Data Supplement). However, the average rolling velocity was decreased by ≈2 times in the graft of TNF-injected animals compared with saline injected mice (Figure 5B and Movies I and IV in the online-only Data Supplement). Interestingly, we found that TNF-mediated leukocyte rolling was significantly inhibited by transduction of Ad-PIAS1-WT but not of Ad-PIAS1-S522A mutant (Figure 5B and Movies V and VI in the online-only Data Supplement).
To investigate the role of PIAS1 S522 phosphorylation in the endothelial inflammation in this model, first we determined VCAM-1 and intercellular adhesion molecule–1 protein expression in the skin graft. Consistent with our in vitro experiments showing mRNA expression of inflammatory genes (Figure 4), overexpression of PIAS1-WT significantly inhibited VCAM-1 and intercellular adhesion molecule–1 protein expression, but compared with PIAS1-WT we could not detect significant inhibitory effects of PIAS1-S522A mutant on the TNF-mediated VCAM-1 and intercellular adhesion molecule–1 induction (Figure 5C). Next, to examine the role of PIAS1 S522 phosphorylation in regulating endothelial VCAM-1 expression in vivo, we injected fluorescent microspheres coated with anti–VCAM-1 into C57BL/6 mice that received transplantation of skin grafts transduced with Ad-LacZ, Ad-PIAS1-WT, or Ad-PIAS1-S522A before 7 days as described above. After 3 hours of TNF treatment we found that the velocity of anti–VCAM-1–coated fluorescent beads was significantly slowed down in Ad-LacZ transduced control. Note that the beads were better-visualized than rolling leukocytes in blood vessels. Overexpression of PIAS1-WT improved bead velocity, but the mutant of PIAS1 S522 failed to do so, suggesting a crucial role of PIAS1 S522 phosphorylation in regulating TNF-mediated endothelial VCAM-1 expression (Figure 5D and 5E, and Movies VII–X in the online-only Data Supplement). These data again suggest a critical role of PIAS1 S522 phosphorylation in endothelial inflammation.
In this study we have uncovered a novel mechanism in ECs through which an inflammatory kinase MK2 can promote transrepression activity of PIAS1 through its S522 phosphorylation. We found that expression of PIAS1 had a transrepressive effect on NF-κB whereas knockdown of PIAS1 reversed this phenotype, a novel finding in ECs. When we examined the relationship between MK2 and PIAS1 in regulating NF-κB transactivation, we found that MK2 phosphorylated PIAS1 S522 (Figure 1C–1E), and this modification enhanced the transrepressive function of PIAS1 on NF-κB (Figure 1F–1H). Furthermore, in contrast to IKKα-mediated S90 PIAS1 phosphorylation, MK2-mediated S522 PIAS1 phoshorylation increased its SUMO E3 ligase activity, then leading to p53-SUMOylation (Figure 2). We found this MK2-mediated p53-SUMOylation increased KLF2 promoter activity as well as subsequent eNOS expression (Figure 3). We also found an anti-inflammatory effect of PIAS1 S522 phosphorylation in vivo (Figure 5). Collectively, our results have revealed a novel negative feedback pathway through which a proinflammatory kinase MK2 plays a unique anti-inflammatory role by regulating both NF-κB transrepression and SUMO E3 ligase activity of PIAS1 via phosphorylation of PIAS1 S522, as shown in Figure 6A.
PIAS1 plays an important role as a transrepressor of NF-κB to regulate inflammation. It has previously been shown that PIAS1 interferes with the DNA-binding ability of p65 by selectively binding to the C terminus region of p65, leading to the inhibition of NF-κB target genes like IκBα in response to TNF.7,18 Furthermore TNF-mediated activation of IKKα not only induces NF-κB transactivation through the canonical TNF–IKKα–NF-κB signaling pathway but also negatively regulates this event by phosphorylating PIAS1 at S90.8 This concept of restrictive inflammatory gene activation through a negative feedback loop is similar to the mechanism we have identified in this study. Similar to IKKα, TNF-mediated activation of MK2 leads to phosphorylation of PIAS1 S522 and inhibits NF-κB transactivation (Figure 1D). Also interesting to note is that the S522 site does not lie in any of the functional domains of PIAS1 that are involved in its binding to p65 or its SUMO E3 ligase activity (a RING-finger-like zinc-binding domain; Figure 6B).19 Possible interplay between S90 and S522 phosphorylation on PIAS1 activity requires further investigation.
Although MK2 did not affect the upstream events of the canonical NF-κB signaling pathway, it enhanced NF-κB transactivation (Figure I in the online-only Data Supplement and Figure 1). Previously, Gorska et al20 have reported that MK2 enhances NF-κB activity by blocking nuclear retention of p38 to prevent excessive phosphorylation of mitogen- and stress-activated protein kinase-1. In turn, by reducing mitogen- and stress-activated protein kinase-1 activity, MK2 prevents p65 export from the nucleus, leading to sustained NF-κB activation. We assume that TNF can simultaneously trigger MK2 to sequester p38 and phosphorylate PIAS1, thereby activating the proinflammatory p38/MK2-mitogen- and stress-activated protein kinase-1 pathway and the newly revealed anti-inflammatory MK2-PIAS1 pathway to form a coordinated regulatory negative feedback loop. This loop is expected to provide a balanced inflammatory response in the physiological state that may become dysregulated in vascular pathologies.
Posttranslational modifications are key regulators of signal transduction because of their ability to transiently alter numerous physiological and pathological pathways. This is especially true in complicated processes like inflammation, in which a careful regulation of signaling is the difference between the physiological and the pathological states. Our study here expands the role of MK2 in endothelial inflammation, by activating a novel negative feedback loop through PIAS1 phosphorylation that can curb pathological inflammation. A disruption to this delicate balance between the proinflammatory and anti-inflammatory roles of MK2 could tip the scale toward endothelial inflammation and dysfunction.
Sources of Funding
This work is supported by grants from the National Institutes of Health to Dr Abe (HL-088637, HL-064839, HL-077789, and HL-102746), Dr Fujiwara (HL-064839 and HL-102746), and Dr Morrell (HL094547 and HL093179). Dr Abe is a recipient of Established Investigator Awards of the American Heart Association (0740013N).
Current address: Chang-Hoon Woo, Department of Pharmacology, College of Medicine, Yeungnam University, Daegu 705-717, Korea.
The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.112.300619/-/DC1
- Received February 2, 2012.
- Accepted October 26, 2012.
- © 2013 American Heart Association, Inc.
- Deguchi JO,
- Aikawa M,
- Tung CH,
- Aikawa E,
- Kim DE,
- Ntziachristos V,
- Weissleder R,
- Libby P
- Liu B,
- Yang R,
- Wong KA,
- Getman C,
- Stein N,
- Teitell MA,
- Cheng G,
- Wu H,
- Shuai K
- Kumar A,
- Kim CS,
- Hoffman TA,
- Naqvi A,
- Dericco J,
- Jung SB,
- Lin Z,
- Jain MK,
- Irani K
- Heo KS,
- Lee H,
- Nigro P,
- Thomas T,
- Le NT,
- Chang E,
- McClain C,
- Reinhart-King CA,
- King MR,
- Berk BC,
- Fujiwara K,
- Woo CH,
- Abe J
- Morrell CN,
- Murata K,
- Swaim AM,
- Mason E,
- Martin TV,
- Thompson LE,
- Ballard M,
- Fox-Talbot K,
- Wasowska B,
- Baldwin WM 3rd.
- Woo CH,
- Shishido T,
- McClain C,
- Lim JH,
- Li JD,
- Yang J,
- Yan C,
- Abe J
- Kumar A,
- Kim CS,
- Hoffman TA,
- Naqvi A,
- Dericco J,
- Jung SB,
- Lin Z,
- Jain MK,
- Irani K
- Jang HD,
- Yoon K,
- Shin YJ,
- Kim J,
- Lee SY
- Gorska MM,
- Liang Q,
- Stafford SJ,
- Goplen N,
- Dharajiya N,
- Guo L,
- Sur S,
- Gaestel M,
- Alam R